| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.CTRV.2009.12.005 |
| P698 | PubMed publication ID | 20079574 |
| P2093 | author name string | Malcolm D Mason | |
| Howard Kynaston | |||
| Mike D Shelley | |||
| P433 | issue | 3 | |
| P921 | main subject | bladder cancer | Q504775 |
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 195-205 | |
| P577 | publication date | 2010-01-15 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses | |
| P478 | volume | 36 |
| Q34866510 | Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy |
| Q64927304 | Advances in risk stratification of bladder cancer to guide personalized medicine. |
| Q35946382 | Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells |
| Q38530663 | Attenuated but live: a pelvic abscess caused by bacille Calmette-Guerin |
| Q33735922 | Bacillus Calmette Guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model |
| Q87838911 | Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis |
| Q49402418 | Case: Bacillus Calmette-Guerin (BCG)-induced Reiter syndrome with an attempt at repeat BCG induction |
| Q34179385 | Ciprofloxacin and epirubicin synergistically induce apoptosis in human urothelial cancer cell lines |
| Q64110901 | Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer |
| Q38807180 | Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review |
| Q47224563 | Correlation of Transabdominal Ultrasonography and Cystoscopy in Follow-up of Patients with Non-muscle Invasive Bladder Cancer. |
| Q30596342 | Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). |
| Q35667739 | Current status of immunotherapy for the treatment of lung cancer. |
| Q35128721 | Current therapeutic strategies for invasive and metastatic bladder cancer. |
| Q37812604 | Developments in intravesical therapy for non-muscle-invasive bladder cancer |
| Q38018207 | Diagnosis and treatment of bladder cancer: how can we improve? |
| Q38369215 | Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles |
| Q36526008 | E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer |
| Q37894687 | Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer |
| Q59790882 | ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes |
| Q38992743 | Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder |
| Q36044627 | GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy |
| Q26739003 | High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage |
| Q46480998 | Highly stable selenadiazole derivatives induce bladder cancer cell apoptosis and inhibit cell migration and invasion through the activation of ROS-mediated signaling pathways |
| Q64069743 | Honokiol induces apoptotic cell death by oxidative burst and mitochondrial hyperpolarization of bladder cancer cells |
| Q47099037 | Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis |
| Q37198053 | In vitro regulation of cell growth and angiogenesis by inositol hexaphosphate in bladder cancer |
| Q35028770 | Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide |
| Q47601017 | Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis |
| Q34166653 | Infection, immunoregulation, and cancer. |
| Q89885924 | Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
| Q24234614 | Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer |
| Q97527244 | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review |
| Q24186083 | Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer |
| Q38924479 | Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. |
| Q40899426 | Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. |
| Q24188295 | Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer |
| Q24203884 | Intravesical gemcitabine for non-muscle invasive bladder cancer |
| Q37982150 | Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review |
| Q26471299 | Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis |
| Q38009095 | Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin |
| Q34073616 | Liver sinusoidal endothelial and biliary cell repopulation following irradiation and partial hepatectomy |
| Q45352123 | Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer |
| Q42324419 | Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute |
| Q38252387 | Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited |
| Q86507875 | Perioperative chemotherapy: when to use it, what to use, and why |
| Q39195452 | Peripheral blood mononuclear cells inhibit proliferation and promote apoptosis of HeLa cells following stimulation with Bacillus Calmette-Guerin |
| Q36046527 | Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin. |
| Q48642623 | Photochemical internalization in bladder cancer - development of an orthotopic in vivo model |
| Q39454622 | Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro |
| Q57966431 | Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity |
| Q37773294 | Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. |
| Q37094285 | Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. |
| Q42773182 | Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates |
| Q42035521 | Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladder |
| Q38928725 | Synthesis and functions of well-defined polymer-drug conjugates as efficient nanocarriers for intravesical chemotherapy of bladder cancer(a). |
| Q54753994 | Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy. |
| Q60681784 | Targeting Toll-Like Receptors for Cancer Therapy |
| Q37991536 | Targeting pattern recognition receptors in cancer immunotherapy. |
| Q38333766 | Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations |
| Q86551271 | The effect of thermochemotherapy with mitomycin C on normal bladder urothelium, an experimental study |
| Q35300254 | The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population |
| Q37944437 | Urothelial carcinoma of the bladder: definition, treatment and future efforts |
| Q91466361 | Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages |
| Q43705778 | Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour |
Search more.